Optimum chemotherapy for ovarian cancer

International Journal of Gynecological Cancer

Volumn 10, Issue SUPPL. 1, 2000, Pages 33-37

  Ozols, R F ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Carboplatin; Chemotherapy; Paclitaxel

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

EID: 0033998030     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.99508.x     Document Type: Article

References (27)

1. Landis SH, Murray T, Bolden S et al. Cancer Statistics, 1999. CA - a Cancer J for Clinicians 1999; 49: 8-31.
2. Eisenhauer EA, Gore ME, Neijt JP. Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner? Ann Oncol 1999; 10: S9-S15.
3. Hoskins WJ, Bundy BN, Thigpen JT et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992; 47: 159-66.
4. Vergote I, De Wever I, Tjalma W et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998; 71: 431-6.
5. van der Burg MEL, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332: 629-34.
6. Advanced Ovarian Cancer Trialists' Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. Br Med J 1991; 303: 884-93.
7. Aabo K, Adams M, Adnitt P et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 1998; 78: 1479-87.
8. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
9. Stuart G, Bertelsen K, Mangioni C et al. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial. Proc Am Soc Clin Oncol 1998; 17: 361a (abstract).
10. Muggia FM, Braly PS, Brady MR et al. Phase III trial of cisplatin or paclitaxel, versus their combination in suboptimal stage III and IVE epithelial ovarian cancer: Gynecologic Oncology Group study #132. Proc Am Soc Clin Oncol 1997; 16: A1257 (abstract).
11. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-22.
12. Vermorken JB, ten Bokkel Huinink WW, Eisenhauer EA et al. Carboplatin versus cisplatin. Ann Oncol 1993; 4: S41-S48.
13. Ozols RF, Bundy BN, Fowler J et al. Randomized phase in study of cisplatin (CIS) /paclitaxel (PAC) versus carboplatin (CARBO) /PAC in optimal stage III epithelial ovarian cancer (OC) Gynecologic Oncology Group Trial (GOG 158). Proc Am Soc Clin Oncol 1999; 18: 356a (abstract).
14. du Bois A, Lueck HJ, Meier W et al. Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial. Proc Am Soc Clin Oncol 1999; 18: 356a (abstract).
15. Neijt JP, Hansen M, Hansen SW et al. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Am Soc Clin Oncol 1997; 16: 352a (abstract).
16. Bookman MA, McGuire WP, Kilpatrick D et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996; 14: 1895-902.
17. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy o ovarian carcinoma. J Clin Oncol 1991; 9: 1668-74.
18. Ahern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726-32.
19. The ICON Collaborators. ICON2. randomized trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 1998; 352: 1571-6.
20. du Bois A, Luck HJ, Bauknecht T et al. First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynakolgische Onkologie Ovarian Cancer Study Group. J Clin Oncol 1999; 17: 46-51.
21. Omura GA, Brady MF, Delmore JE et al. A randomized trial of paclitaxel (T) at 2 dose levels and filgrastrim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG Study. Proc Am Soc Clin Oncol 1996; 15: 280 (abstract).
22. Rosenberg P, Andersen H, Boman K et al. A randomized multicenter study of single agent paclitaxel (Taxol) given weekly versus every three weeks to patients (PTS) with ovarian cancer (OC) previously treated with platinum therapy. Proc Am Soc Clin Oncol 1999; 18: 368a (abstract).
23. Jakobsen A, Bertelsen K, Andersen JE et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group Study. J Clin Oncol 1997; 15: 193-8.
24. Gore M, Mainwaring P, Macfarlane V et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol 1998; 16: 2426-34.
25. Thigpen T. Dose-intensity in ovarian carcinoma: Hold, enough? J Clin Oncol 1997; 15: 1291-3.
26. Hansen SW, Anderson H, Boman K et al. Gemcitabine, carboplatin, and paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO stages IIB-IV. Proc Am Soc Clin Oncol 1999; 18: 357a (abstract).
27. Hoskins P, Eisenhauer E, Fisher B et al. Sequential couplets of cisplatin (DDP) /topotecan (TOP) and cisplatin/ paclitaxel (T) as first-line therapy for advanced epithelial ovarian cancer (EOC): an NCIC Clinical Trials Group Phase II Study. Proc Am Soc Clin Oncol 1999; 18: 357a (abstract).